Science Corporation
Developing neural-engineering devices to restore vision and address cognition and mobility.
Website: https://science.xyz/
Cover Block
Publicly reported
| Field | Detail |
|---|---|
| Name | Science Corporation |
| Tagline | Developing neural-engineering devices to restore vision and address cognition and mobility. |
| Headquarters | Alameda, California, US [Science Corporation] |
| Founded | 2021 [Science Corporation] |
| Stage | Series D+ [TechCrunch, November 2026] |
| Business model | Hardware + Software |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (2), Max Hodak and Emma Zhou [TechCrunch, December 2025] [Science Corporation, Retrieved 2026] |
| Funding label | $100M+ |
| Total disclosed | Approximately $630,000,000, based on the disclosed $230,000,000 Series C and $400,000,000 Series D [Business Wire, March 2026] [TechCrunch, November 2026] |
Links
Publicly reported
- Website: https://science.xyz/
Summary and Signal
PUBLIC Science Corporation is an Alameda-based clinical-stage medical technology company building neural-engineering devices, and it merits investor attention now because its lead retinal implant has moved from clinical evidence into early European commercialization while the company has also raised a fresh $400 million at a reported $3.5 billion valuation [Science Corporation] [Morningstar / Business Wire, September 2026] [TechCrunch, November 2026]. Founded in 2021 by Max Hodak and Emma Zhou, the company is pursuing a narrow initial wedge in vision restoration rather than a broad, near-term claim on general-purpose brain-computer interfaces, which makes the current operating story easier to underwrite than the category's more expansive ambitions [Science Corporation] [TechCrunch, December 2025] [Science Corporation, Unknown].
The lead product, PRIMA, combines a subretinal photovoltaic implant with near-infrared light-projecting glasses to restore functional central vision in patients with geographic atrophy, and the key point for investors is that the device now carries a European CE mark and was reported to be commercially prescribed and implanted in Europe and the U.K. by September 2026 [PMC, Retrieved 2026] [Morningstar / Business Wire, September 2026] [MedTech Dive, November 2026]. That gives Science a more concrete commercialization pathway than many neurotechnology peers, although U.S. regulatory progress still appears to be ahead rather than in hand [MedTech Dive, November 2026].
The founder-market fit is one of the clearer parts of the file. Hodak is the company's founder and CEO, previously served as co-founder and president of Neuralink, and earlier co-founded Transcriptic, while Zhou is identified by the company as a co-founder and director of BCI research [TechCrunch, December 2025] [The New York Times, July 2019] [Forbes, April 2016] [Science Corporation, Retrieved 2026].
On financing, the public record supports two large recent rounds: a $230 million Series C in March 2026 and a $400 million Series D in November 2026, with participation across venture, strategic, and healthcare-linked investors including Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT, Quiet Capital, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, and PLC Neurotech [Business Wire, March 2026] [TechCrunch, November 2026]. The business model is best understood as hardware plus software sold through physician- and clinic-led deployment, with PRIMA as the clinical lead asset and adjacent research tools providing a secondary commercial surface [MedTech Dive, November 2026] [Bloomberg, October 2024] [Science Corporation, Retrieved 2026].
Over the next 12 to 18 months, the questions are straightforward: whether European implantation converts into repeatable commercial uptake, whether U.S. authorization advances on a visible timetable, and whether Science can broaden from a single flagship indication without losing regulatory focus [Morningstar / Business Wire, September 2026] [MedTech Dive, November 2026]. The financing gives the company room to attempt that transition, but the investable debate still turns on execution at the clinic level, not only on technical ambition [TechCrunch, November 2026] [Business Wire, March 2026].
One source, partially checked -- Relies on a mix of company materials and single-source reporting, with partial corroboration from TechCrunch, MedTech Dive, Business Wire, and Science's own disclosures.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series D+ |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | $100M+ (total disclosed ~$630,000,000) |
Company Overview
PUBLIC Science Corporation presents first as a clinical-stage medtech company with a narrower initial entry point than its long-term ambition suggests. The company is based in Alameda, California, and was founded in 2021 by Max Hodak and Emma Zhou, according to its website and the source-grounded company profile provided for this report [Science Corporation] [Science Corporation]. Its public description centers on neural-engineering devices, with vision restoration as the clearest near-term commercial focus [Science Corporation].
The chronology that can be verified from company-controlled sources is concise but material. Science was founded in 2021 [Science Corporation]. By March 2026, the company announced a $230 million Series C tied to commercialization of its PRIMA retinal implant program [Science Corporation]. By July 2026, PRIMA had received a European CE mark, and by September 2026 the company stated that doctors in Europe and the U.K. were prescribing and implanting the system commercially [Science Corporation]. The same September 2026 company announcement also disclosed that Darius Shahida had been named president, a sign that Science was adding commercialization and operating structure alongside product development [Science Corporation].
What stands out is that the public company narrative is already moving from research orientation toward regulated-market execution. The website and company news flow frame Science not as a general-purpose brain-computer interface platform company first, but as a developer of specific neural-engineering products now entering commercial use in Europe, at least for its lead ophthalmology program [Science Corporation] [Science Corporation]. That distinction matters because the next leg of company building will likely be judged less by technical promise alone and more by evidence of clinical adoption, manufacturing readiness, and regulatory progress.
One source, partially checked -- This section relies primarily on company website and company news materials, with partial corroboration from the structured company profile.
The Product and the Stack
MIXED
Science Corporation is clearest, in public evidence, when it narrows from broad neural-engineering ambition to one device and one care pathway. The lead product is PRIMA, a retinal implant system for vision loss caused by geographic atrophy, and multiple sources describe the system as a combination of implantable retinal hardware and special glasses that capture and process images before projecting them to the implant with near-infrared light [Science Corporation] [MedTech Dive, November 2026] [PMC]. Morningstar's reprint of the company's September 2026 announcement adds the most commercially relevant step: PRIMA received a European CE mark in July 2026 and was being commercially prescribed and implanted by doctors in Europe and the U.K. by September 2026 [Morningstar / Business Wire, September 2026].
The clinical signal is promising, but the public record still mixes peer-reviewed evidence with company-led framing. Science has publicized that The New England Journal of Medicine reported PRIMA restored functional central vision in patients with geographic atrophy, and third-party coverage also points to clinical results and durable follow-up, including a 36-month update cited in October 2026 press coverage [Science Corporation] [Morningstar, October 2025] [Business Wire, October 2026] [Eyewire+]. That is enough to say the product has moved beyond concept stage and into regulated commercial use in Europe, but not enough to generalize about long-term outcomes, reimbursement, or U.S. authorization timing from the sources here [MedTech Dive, November 2026].
Outside PRIMA, the company also sells research hardware that appears designed to support neural-interface development rather than direct patient care. Bloomberg reported in 2024 that Science had introduced products aimed at lowering cost and development time for research labs and startups working on brain interfaces, while the company site describes WiFi-enabled headstages for neural stimulation and data acquisition; pricing on the public materials is inconsistent across sources, with Science listing SciFi 2 from $2,048 for academic customers and an earlier company post listing SciFi at $1,024 for preorder [Bloomberg, October 2024] [Science Corporation] [Science Corporation, Retrieved 2026]. The through-line is a dual product strategy: a clinical retinal implant platform on one side, and enabling tools for researchers on the other.
One source, partially checked -- Supported by MedTech Dive, Morningstar / Business Wire, PMC, and company materials, with some product-detail and pricing claims still relying on company sources or single-publication coverage.
The Market They Are Entering
PUBLIC
The market matters now because Science is trying to commercialize a retinal implant at the point where clinical evidence, European regulatory clearance, and investor appetite for neurotechnology have started to line up, but the underlying market size still has to be inferred from adjacent public evidence rather than company-specific market studies [Morningstar / Business Wire, September 2026] [TechCrunch, November 2026].
The public record here is narrower than investors might like. None of the captured third-party sources provides a verified TAM, SAM, or SOM for PRIMA itself, so the cleanest approach is to anchor on the addressable disease and device context rather than force a synthetic number. PRIMA is aimed at vision loss caused by geographic atrophy associated with age-related macular degeneration, and the cited literature describes the system as a subretinal photovoltaic implant paired with near-infrared light-projecting glasses for areas of central retinal atrophy [PMC] [MedTech Dive, November 2026]. That places Science at the intersection of implantable ophthalmology, neurotechnology, and age-related vision restoration, a category that is narrower than the full BCI market but materially more concrete because the initial buyer pathway runs through ophthalmic specialists rather than a general consumer channel [MedTech Dive, November 2026] [Morningstar / Business Wire, September 2026].
Demand drivers are easier to substantiate than market size. First, the disease burden sits in an aging population, which tends to support durable demand for interventions that preserve or restore functional vision, especially where existing options are limited or aimed at slowing decline rather than restoring central sight. Second, PRIMA has moved beyond preclinical narrative into a regulated commercial setting in Europe and the U.K., after receiving a CE mark in July 2026 and being commercially prescribed and implanted by September 2026, according to the company announcement carried by Business Wire and Morningstar [Morningstar / Business Wire, September 2026]. Third, the company and third-party coverage point to a clinical evidence base that investors can underwrite more directly than broader neurotech claims, including New England Journal of Medicine coverage of functional central vision restoration and company-reported 36-month durability data for patients with geographic atrophy [Science Corporation] [Business Wire, October 2026] [Eyewire+].
Adjacent markets matter because Science is not operating in a single-product vacuum. Bloomberg reported in 2024 that the company had introduced additional products intended to reduce cost and development time for research labs and startups working on neural interfaces, which suggests an ecosystem strategy around tooling as well as therapeutics [Bloomberg, October 2024]. The company site also markets headstages that process, store, and transmit signals to and from neural interface devices over WiFi, with listed academic pricing for SciFi 2 starting at $2,048, a reminder that part of the commercial surface area may resemble research instrumentation rather than only implanted medical devices [Science Corporation] [Science Corporation, Retrieved 2026]. For market framing, that means the nearest substitutes are not only retinal implants, but also low-vision assistive technologies, ophthalmic procedures, and other neurotechnology platforms competing for capital, talent, and regulatory attention [MedTech Dive, November 2026] [Bloomberg, October 2024].
Regulation is the main force shaping how quickly this market can open. Europe has given Science an earlier commercial path through CE marking across 30 European countries, according to trade and company-linked coverage, while U.S. availability remains subject to FDA review and a more gradual evidence and authorization process [Ophthalmology Times Europe] [BioSpace] [MedTech Dive, November 2026]. That divergence matters because the initial service model is physician-led and procedure-based, so market expansion is constrained not just by patient need but by surgeon adoption, reimbursement development, and country-by-country hospital uptake. The same dynamic cuts both ways: once a device is cleared and implant workflows are established, regulated medtech can become harder for later entrants to displace than software-only health products [Morningstar / Business Wire, September 2026] [MedTech Dive, November 2026].
| Market lens | What public sources support | Relevance to Science |
|---|---|---|
| Geographic atrophy vision restoration | PRIMA targets geographic atrophy associated with age-related macular degeneration [PMC] [MedTech Dive, November 2026] | Defines the initial clinical market more precisely than generic BCI framing |
| European commercial rollout | CE mark in July 2026, followed by prescribing and implantation in Europe and the U.K. by September 2026 [Morningstar / Business Wire, September 2026] | Indicates the market is moving from trial setting to early commercial adoption |
| Neurotech research tools | Science launched lower-cost products for research labs and startups, according to Bloomberg [Bloomberg, October 2024] | Expands the adjacent market beyond a single therapeutic device |
| U.S. regulatory pathway | U.S. commercialization remains subject to FDA review [MedTech Dive, November 2026] | Keeps the largest medtech revenue pool conditional rather than realized |
The evidence supports a market that is real and medically consequential, but still better framed as an emerging subsegment of ophthalmic neurotechnology than as a fully quantified category. For now, the strongest public signal is not a TAM figure. It is the progression from clinical validation to CE-marked commercial use, which tends to matter more than broad neurotech market rhetoric at this stage [Morningstar / Business Wire, September 2026] [TechCrunch, November 2026].
One source, partially checked -- Section relies on credible third-party reporting and literature for product indication, CE-marked commercialization, and regulatory posture, but no independent named source in the provided record offers a verified TAM, SAM, or SOM for PRIMA or its immediate category.
The Competitive Field
MIXED Science Corporation is positioned less as a general-purpose brain-computer interface developer than as a retinal-implant company trying to turn a narrow regulatory and clinical lead into a broader neural-engineering platform [Science Corporation] [MedTech Dive, November 2026] [Morningstar / Business Wire, September 2026].
The competitive map is unusual because the closest pressure does not come from named direct peers in the supplied record, but from three adjacent groups that matter for adoption. First are incumbent ophthalmic care pathways for geographic atrophy and advanced AMD, where the alternative to an implant is specialist medical management and low-vision support rather than another confirmed retinal BCI vendor in this dataset [PMC] [Morningstar, October 2025]. Second are broader neurotechnology developers, where Max Hodak's prior Neuralink background places Science in a field that investors and media already understand, even if the company is pursuing the eye rather than the cortex as its initial clinical wedge [TechCrunch, December 2025] [The New York Times, July 2019]. Third are research-tool suppliers and lab infrastructure vendors, where Science's SciFi headstage and related ecosystem products suggest a separate, earlier-revenue surface that could build developer familiarity without being the same business as PRIMA implantation [Bloomberg, October 2024] [Science Corporation].
Science's edge today looks strongest on regulation, capital, and founder-market fit, but each of those advantages has limits. PRIMA had received a CE mark in July 2026 and was being commercially prescribed and implanted in Europe and the U.K. by September 2026, which gives Science a public claim to real-world deployment that many neurotech programs never reach [Morningstar / Business Wire, September 2026] [Ophthalmology Times Europe]. The company also closed a $230 million Series C in March 2026 and a $400 million Series D in November 2026, giving it a disclosed late-stage financing base that can support commercialization and clinical work at the same time [Business Wire, March 2026] [TechCrunch, November 2026]. That said, the regulatory edge is perishable if U.S. authorization lags and if European uptake proves slower than the funding base implies, because capital alone does not create surgeon adoption or reimbursement durability [MedTech Dive, November 2026].
The clearest exposure is that Science does not appear to control the full clinical channel yet, and the record does not establish a proprietary hospital network, exclusive distribution system, or payer advantage [Morningstar / Business Wire, September 2026] [MedTech Dive, November 2026]. Tenet Healthcare appears in the Series D investor list, but the available public reporting does not establish that as a deployment or procurement relationship, so it should not be read as a locked-in commercialization moat [TechCrunch, November 2026]. Neuralink is the named company with the strongest public mindshare advantage in adjacent neurotechnology because of its visibility and founder history, even though the product pathway differs materially from PRIMA's retinal approach [The New York Times, July 2019] [TechCrunch, December 2025]. In ophthalmology itself, Science is also exposed to substitute therapies and conservative physician behavior, since an implant-plus-glasses system must win on functional outcomes, training burden, and clinical workflow, not just technical novelty [PMC] [MedTech Dive, November 2026].
The most plausible 18-month scenario is a split outcome between commercialization and platform narrative. Winner if X: Science, if PRIMA's post-CE European rollout translates into reproducible implantation volume and cleaner evidence for U.S. review, because that would turn a promising clinical asset into a category-defining commercial reference point in vision restoration [Morningstar / Business Wire, September 2026] [Business Wire, October 2026]. Loser if Y: Neuralink, in the narrower investor narrative around near-term therapeutic proof, if high-profile cortical BCI programs remain earlier-stage while Science continues to show deployed use in a defined blindness population [TechCrunch, December 2025] [TechCrunch, November 2026]. The reverse can also happen: if PRIMA's rollout stalls or reimbursement remains opaque, then Science risks being outflanked in attention and talent markets by better-known neurotech platforms whose clinical timelines are longer but whose narratives travel more easily [MedTech Dive, November 2026] [Bloomberg, November 2026].
Opportunity
PUBLIC
The prize here is unusually large for a clinical-stage medtech company, because success would not stop at a single implant, it would establish Science Corporation as one of the few scaled commercial platforms connecting implantable neural hardware, external compute, clinical deployment, and a broader developer toolchain for brain and retinal interfaces [Science Corporation] [TechCrunch, November 2026] [Bloomberg, November 2026].
The headline opportunity is straightforward: become the first broadly commercial neural-interface company with a real product footprint in vision restoration, then use that foothold to expand into adjacent neural-engineering categories. That outcome is still conditional, but it is not purely aspirational. PRIMA received a European CE mark in July 2026 and was being commercially prescribed and implanted in Europe and the U.K. by September 2026, which matters because it moves the company from a research narrative into early commercial execution [Morningstar / Business Wire, September 2026] [Ophthalmology Times Europe]. TechCrunch reported a $400 million Series D at a $3.5 billion valuation in November 2026, and MedTech Dive described the financing as support for commercialization of the BCI device, suggesting investors are underwriting a go-to-market phase rather than only long-horizon R&D [TechCrunch, November 2026] [MedTech Dive, November 2026]. The clinical signal also appears stronger than a typical pre-revenue hardware claim set: Science publicized New England Journal of Medicine coverage of PRIMA results, and third-party summaries describe restored functional central vision in patients with geographic atrophy, with 36-month durability data also reported in 2026 coverage [Science Corporation] [Morningstar, October 2025] [Business Wire, October 2026].
A plausible path to very large scale depends on more than one product path, which is why the upside needs to be thought about in scenarios rather than a single base case.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| PRIMA becomes the first scaled commercial retinal BCI franchise | Science turns a CE-marked implant into a standard referral option for eligible geographic atrophy patients across Europe, then uses that installed clinical base to support U.S. expansion if FDA review progresses | European commercial rollout and continued clinical publication cadence [Morningstar / Business Wire, September 2026] [MedTech Dive, November 2026] | PRIMA already has CE mark authorization and reported commercial prescribing and implantation in Europe and the U.K., which is a stronger starting point than a pre-approval concept story [Morningstar / Business Wire, September 2026] [BioSpace] |
| Neural-interface platform, not single-product medtech | The company uses PRIMA credibility plus its headstage and ecosystem tools to serve both clinical and research customers, creating a shared hardware and software stack across implant programs | Broader adoption of Science ecosystem products and continued investment in commercialization infrastructure [Science Corporation] [Bloomberg, October 2024] | Bloomberg reported that Science had introduced products aimed at lowering cost and development time for research labs and startups, which supports the idea of a parallel tools business around the core clinical effort [Bloomberg, October 2024] |
| Strategic healthcare channel expansion | Science converts investor relationships into distribution, clinical access, or commercialization partnerships that widen deployment beyond a narrow specialty launch | Participation from healthcare-linked investors and operators in later financing rounds [TechCrunch, November 2026] [Business Wire, March 2026] | The disclosed investor base includes Tenet Healthcare in the Series D syndicate and multiple repeat venture backers, which does not prove channel access but does make partnership formation more plausible than for a standalone lab-stage company [TechCrunch, November 2026] [Business Wire, March 2026] |
The compounding effect, if it emerges, would likely come from three linked loops. First, every successful implant and follow-up dataset can improve physician confidence and referral behavior in a category where clinical adoption is earned slowly, not marketed into existence [Morningstar / Business Wire, September 2026] [Business Wire, October 2026]. Second, a commercial retinal program creates a regulatory, manufacturing, and reimbursement learning base that can be reused across later neural-interface products, which is one reason later-stage investors may be willing to fund the company at multibillion-dollar scale before broad revenue disclosure [TechCrunch, November 2026] [Bloomberg, November 2026]. Third, the company is not presenting only an implant thesis. Its ecosystem products for labs and device developers suggest an attempt to seed technical standards around its hardware and signal-processing stack, which could make Science more embedded in the category even before additional therapeutic devices mature [Science Corporation] [Bloomberg, October 2024]. That is not a network effect in the consumer-software sense, but it is a form of platform lock-in if clinicians, researchers, and future partners build around the same architecture.
The size of the win can be framed through the only public market signal available in the source set: investors reportedly valued Science at $3.5 billion after the November 2026 Series D, up from a reported $1.3 billion valuation attached to the Series C in database coverage, though that earlier figure is less well corroborated [TechCrunch, November 2026] [FundBat]. If the company converts PRIMA from an early commercial implant into the leading neural-interface franchise in vision and proves it can extend the stack into adjacent applications, an outcome in the high single-digit to low double-digit billions is conceivable (scenario, not a forecast). That would imply roughly 2x to 4x from the latest reported private valuation, which is a meaningful but not unrealistic upside range for a company attempting to define a new clinical platform category rather than win a narrow device niche [TechCrunch, November 2026] [Bloomberg, November 2026]. The evidence in hand supports the existence of that upside path. It does not yet prove duration, reimbursement breadth, or U.S. regulatory conversion, which is why the opportunity remains large and conditional at the same time.
One source, partially checked -- Section relies on TechCrunch, MedTech Dive, Morningstar / Business Wire, Bloomberg, and company materials for funding, commercialization, and product-platform claims; several upside inferences remain scenario-based rather than independently verified outcomes.
Sources
Publicly reported
[Science Corporation] Science | Science Corporation | https://science.xyz/
[TechCrunch, November 2026] Science Corporation's brain tech is worth $3.5 billion after new funding | https://techcrunch.com/2026/11/17/science-corporations-brain-tech-is-worth-3-5-billion-after-new-funding/
[TechCrunch, December 2025] After Neuralink, Max Hodak is building something even wilder | https://techcrunch.com/2025/12/05/after-neuralink-max-hodak-is-building-something-stranger/
[Business Wire, March 2026] Science Corporation Closes $230 Million Series C to Accelerate Commercialization of Its PRIMA BCI Retinal Implant, the World’s Most Advanced Vision Restoration Technology | https://www.businesswire.com/news/home/20260305896789/en/Science-Corporation-Closes-$230-Million-Series-C-to-Accelerate-Commercialization-of-Its-PRIMA-BCI-Retinal-Implant-the-Worlds-Most-Advanced-Vision-Restoration-Technology
[Morningstar / Business Wire, September 2026] Science Corporation Names Darius Shahida as President | https://www.morningstar.com/news/business-wire/20260917593792/science-corporation-names-darius-shahida-as-president
[MedTech Dive, November 2026] Science Corporation raises $400M to commercialize BCI device | https://www.medtechdive.com/news/science-corporation-raises-400m-to-commercialize-bci-device/875009/
[PMC, Retrieved 2026] The PRIMA system combines a subretinal photovoltaic implant and near-infrared light-projecting glasses to restore sight to areas of central retinal atrophy | https://pmc.ncbi.nlm.nih.gov/
[The New York Times, July 2019] Elon Musk’s Neuralink Wants ‘Sewing Machine-Like’ Robots to Wire Brains to the Internet | https://www.nytimes.com/2019/07/16/technology/neuralink-elon-musk.html
[Forbes, April 2016] The Life Science Startup That Wants To Make Research Reproducible | https://www.forbes.com/sites/matthewherper/2016/04/26/the-life-science-startup-that-wants-to-make-research-reproducible/
[Bloomberg, November 2026] Bill Ackman-Backed Retina Implant Startup Science Corp. Valued at $3.5 Billion | https://www.bloomberg.com/profile/company/2212835D:US
[Science Corporation, Retrieved 2026] Science Corporation is a clinical-stage medical technology company | Science Corporation | https://science.xyz/company/
[Morningstar, October 2025] PRIMA restored functional central vision to patients suffering from geographic atrophy due to age-related macular degeneration | https://www.morningstar.com/
[Business Wire, October 2026] PRIMA BCI clinical trial showed durable vision restoration at 36 months in blind patients suffering from geographic atrophy caused by age-related macular degeneration | https://www.businesswire.com/
[Eyewire+] The New England Journal of Medicine Reports Science Corp.’s PRIMA BCI Implant Restores Functional Central Vision to Patients with Geographic Atrophy Caused By Age-Related Macular Degeneration | https://eyewire.news/
[Bloomberg, October 2024] Science Corp. has several new products designed to bring down the cost and development time for research labs and startups looking to probe the mind | https://www.bloomberg.com/
[Ophthalmology Times Europe] PRIMA received a CE mark under the European Union Medical Device Regulation from Deutscher Kraftfahrzeug-Überwachungs-Verein e.V, authorizing its commercial availability in 30 European countries | https://europe.ophthalmologytimes.com/
[BioSpace] PRIMA received a CE mark under the European Union Medical Device Regulation from DEKRA, authorizing its commercial availability across 30 European countries | https://www.biospace.com/
Articles about Science Corporation
- Science Corporation's Retinal Implant Is Now Prescribed in Europe — The company's PRIMA brain-computer interface, backed by $630 million, has received a CE mark and is being implanted for a specific form of blindness.